Charles River Laboratories (CRL) reported $1.03 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 0.6%. EPS of $3.12 for the same period compares to $2.80 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $982.87 million, representing a surprise of +5.01%. The company delivered an EPS surprise of +24.8%, with the consensus EPS estimate being $2.50.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Research Models and Services: $213.27 million compared to the $205.52 million average estimate based on three analysts. The reported number represents a change of +3.3% year over year.
- Revenue- Discovery and Safety Assessment: $618.03 million compared to the $581.16 million average estimate based on three analysts. The reported number represents a change of -1.5% year over year.
- Revenue- Manufacturing Solutions: $200.84 million versus $191.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
- Revenue- Service: $840.84 million versus the two-analyst average estimate of $807.44 million. The reported number represents a year-over-year change of -0.2%.
- Revenue- Product: $191.3 million versus $178.09 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
- Operating income- Research Models and Services- Non-GAAP: $53.88 million versus the three-analyst average estimate of $47.82 million.
- Operating income- Discovery and Safety Assessment- Non-GAAP: $169.17 million compared to the $139.53 million average estimate based on three analysts.
- Operating income- Manufacturing Solutions- Non-GAAP: $65.84 million versus the three-analyst average estimate of $50.74 million.
- Operating income- Unallocated Corporate Overhead: $-70.49 million compared to the $-48.86 million average estimate based on three analysts.
- Operating income- Research Models and Services: $35.79 million compared to the $26.1 million average estimate based on two analysts.
- Operating income- Discovery and Safety Assessment: $122.78 million versus $105.25 million estimated by two analysts on average.
- Operating income- Manufacturing Solutions: $12.06 million versus the two-analyst average estimate of $19.72 million.
View all Key Company Metrics for Charles River here>>>
Shares of Charles River have returned +5.8% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Charles River Laboratories International, Inc. (CRL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
